Skip to content

Nuvation Bio NUVB Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Pfizer logo
PfizerPFE
0.7×0.0×
Immunome logo
ImmunomeIMNM
0.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
0.0×
Arcus Biosciences logo
Arcus BiosciencesRCUS
0.2×+0.1×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
8.4×+6.9×

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

Based on the most recent quarter.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's debt-to-equity?
Nuvation Bio (NUVB) reported debt-to-equity of 0.2× in Q1 2026.
How has Nuvation Bio's debt-to-equity changed year-over-year?
Nuvation Bio's debt-to-equity increased by 557.4% year-over-year, from 0× to 0.2×.
What is the long-term trend for Nuvation Bio's debt-to-equity?
Over 5 years (2020 to 2025), Nuvation Bio's debt-to-equity has grown at a 57.9% compound annual growth rate (CAGR), from 0× to 0.2×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.